euro-biopharma-2018-keynote

Notes:

conference

series LLC Ltd

September 18-19, 2018 | Amsterdam, Netherlands

European Biopharma Congress

Euro Biopharma 2018

Clinical Pharmacology & Biopharmaceutics | ISSN : 2167-065X

Volume 7

Page 18

Bimal Roy Krishna, Clin Pharmacol Biopharm 2018, Volume:7

DOI: 10.4172/2167-065X-C1-027

Psychotropic drugs and pregnancy

During pregnancy psychiatric disorder may occurs requiring appropriate therapy.

These conditions may also be preexisting which require careful diagnosis and

monitoring. While it is essential to treat such conditions, pregnancy limits the use of

psychotropic drugs due to potential adverse fetal outcomes and possibly teratogenicity.

Understandably improvement of the disease state may provide benefit to the

developing fetus. Recent studies show that up to 20% of women suffer from mood or

anxiety disorders during pregnancy. Depression and anxiety during pregnancy have

been associated with a variety of adverse pregnancy outcomes. Women who suffer

from psychiatric illness during pregnancy are less likely to receive adequate prenatal

care and are more likely to abuse alcohol, tobacco, and other substances known to

adversely affect pregnancy outcomes. IUGR, low birth weight and fetal growth

retardation in children born to depressed mothers have been documented. Preterm

delivery is another potential complication with an increased risk of pre-eclampsia,

operative delivery, and infant admission to a special care nursery for a variety of

conditions including respiratory distress, hypoglycemia, and prematurity. A number

of non-pharmacological options are available including cognitive behavioral and

interpersonal psychotherapy. Nevertheless a considerable percentage of patients will

need pharmacological intervention keeping in mind that a number of psychotropic

medications may treat more than one condition. This presentation covers maternal

mental illness and pregnancy outcome and current therapeutic interventions and

guidelines.

Biography

Bimal Roy Krishna is currently Professor and Director of Pharmacology at the College of Osteopathic Medicine,

Touro University in Nevada. He obtained a Bachelor of Science (First Class Honors) in Pharmacology and

Physiology and a Doctor of Philosophy, Medicine (OB/GYN/Pharmacology) fromMonash University inAustralia. He

also teaches for the Step 1 USMLE and COMLEX reviews for Kaplan Medical throughout the United States and in

UAE, Europe, Saudi Arabia, India, Mexico and the Caribbean. He has been teaching online for Kaplan University

for over seven years. He has contributed to numerous publications and is a Member of a number of organizations

including Fellow-American College of Clinical Pharmacology. His research background is in Maternal and Neonatal

Pharmacology, specifically looking at materno-fetal transfer utilizing the perfused human placental and cultured

syncytiotrophoblast model. Complementary and Alternative Medicine is another area of his interest.

Bimal Roy Krishna

Touro University, USA